# The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants

> **NCT04424264** · PHASE1 · COMPLETED · sponsor: **Professor Francois Venter** · enrollment: 18 (actual)

## Conditions studied

- HIV-1-infection
- Tuberculosis

## Interventions

- **DRUG:** Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid
- **DRUG:** Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid
- **DRUG:** Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz

## Key facts

- **NCT ID:** NCT04424264
- **Lead sponsor:** Professor Francois Venter
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-05
- **Primary completion:** 2020-10-30
- **Final completion:** 2020-10-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04424264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04424264, "The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04424264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*